Berry Oncology Closes US$99.15M Series B1 Funding

Berry Oncology Completes Series B1 Funding

Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.

This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.

The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.

Established in August 2017 and led by Zhou Jun, CEO, Berry Oncology leverages technology, business channels and capital of its predecessor Berry Genomics, a leader in genetics research, to complete genetic testing product service system for high-risk populations and patients of cancers. Up till now, it has been working with over 700 hospitals in China and has provided genetic testing of cancers for hundreds of thousands of cancer patients.

In less than a year, Berry Oncology has raised about US$154.4 million and nearly US$309 million since its establishment.

Berry Oncology has three centers (manufacture, supercomputing, R&D) located in Fuzhou and Beijing.